Curis
Curis' revenue fell 13.4% to $9 million in fiscal 2025. Its operating margin was −60.5%, up from −408.3% a year earlier. The diluted share count rose 108.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Curis lost money in fiscal 2025: a net loss of $8 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 140 | 86 | 56 | 20 | 5 |
| Debt incl. finance leases | 0 | 0 | 8 | 8 | 0 |
| Net debt (negative means net cash) | −140 | −86 | −48 | −12 | −5 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.4x | — | 0.0x |
| Interest coverage | — | −12.9x | −20.5x | −96.6x | −3.7x |
| Current ratio | 9.1x | 9.2x | 2.8x | 1.4x | 0.5x |
| Quick ratio | 9.1x | 9.2x | 2.8x | 1.4x | 0.5x |
Cash flow
Projections
Project Curis' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $5,500 of Curis shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Kenneth I KaitinDirector | Bought | 10,000 | $0.55 | $5,500 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 2 of 8 | 3 of 8 |
| Rule of 40 | −384.8% | — | — |
| Altman Z'' | −51.01 | −104.16 | −207.55 |
| Accruals ratio | −9.7% | −6.5% | 64.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 2 of 8 | 2 of 8 | 3 of 8 |
Compare
Put Curis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Curis | FY25 | −13.4% | −60.5% | — | — | — | 3 | |
| Prothena | FY25 | −92.8% | −2,216.4% | — | — | — | — | Compare |
| Taysha Gene Therapies | FY25 | 17.3% | −1,130.7% | −960.1% | — | — | 4 | Compare |
| BioAge Labs | FY25 | — | −1,031.5% | −915.5% | — | — | 4 | Compare |
| Innate Pharma SA | FY25 | −55.2% | −599.8% | −587.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 8 | 10 | 10 | 10 | 11 | 11 | 10 | 10 | 11 | 9 |
| Revenue growth | −4.5% | 31.5% | 5.3% | −4.1% | 8.3% | −1.7% | −4.6% | −1.4% | 8.8% | −13.4% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 18 | 45 | 24 | 22 | 23 | 35 | 43 | 40 | 39 | 28 |
| Operating income | −58 | −50 | −29 | −24 | −25 | −42 | −53 | −48 | −44 | −6 |
| Net income | −60 | −53 | −33 | −32 | −30 | −45 | −57 | −47 | −43 | −8 |
| Diluted EPS (US$) | −45.00 | −35.80 | −19.60 | −19.40 | −12.20 | — | −12.14 | −8.96 | −6.88 | −0.58 |
| Diluted shares (millions) | 1 | 2 | 2 | 2 | 2 | 5 | 5 | 5 | 6 | 13 |
| Cash flow | ||||||||||
| Cash from operations | −36 | −48 | −30 | −26 | −26 | −38 | −54 | −38 | −40 | −27 |
| Capital expenditure | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | — | — |
| Free cash flow | −36 | −49 | −30 | −26 | −26 | −38 | −55 | −38 | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 4 | 5 | 4 | 3 | 3 | 5 | 7 | 6 | 6 | 4 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 44 | 60 | 24 | 20 | 183 | 140 | 86 | 56 | 20 | 5 |
| Debt incl. finance leases | 20 | 42 | 36 | 0 | 1 | 0 | 0 | 8 | 8 | 0 |
| Total assets | 58 | 74 | 37 | 35 | 204 | 162 | 109 | 77 | 41 | 20 |
| Total liabilities | 28 | 50 | 42 | 69 | 74 | 72 | 62 | 58 | 47 | 14 |
| Shareholders' equity | 30 | 24 | −4 | −34 | 131 | 91 | 47 | 20 | −6 | 6 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −771.1% | −502.7% | −281.3% | −243.5% | −229.8% | −395.0% | −521.8% | −482.2% | −408.3% | −60.5% |
| Net margin | −802.6% | −538.7% | −312.4% | −321.3% | −276.0% | −426.7% | −557.7% | −473.0% | −397.8% | −80.3% |
| Free cash flow margin | −480.1% | −490.4% | −289.1% | −262.4% | −243.8% | −353.3% | −538.8% | −383.5% | — | — |
| Rule of 40 (growth + FCF margin) | −484.6% | −458.9% | −283.8% | −266.4% | −235.5% | −355.0% | −543.4% | −384.8% | — | — |
| Return on capital | — | — | −385.1% | — | — | — | — | — | — | — |
| Return on equity | −128.6% | −199.5% | −334.1% | — | −61.8% | −41.0% | −82.6% | −143.2% | −634.7% | — |
| Return on assets | −79.1% | −81.1% | −58.6% | −88.7% | −25.0% | −24.8% | −41.8% | −51.0% | −73.2% | −24.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |